Page 171 - HIV/AIDS Guidelines

References

1. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir
Immune Defic Syndr. Dec 1 2006;43(Suppl 1):S149-155.

2. World Heath Organization (WHO). Adherence to long term therapies – evidence for action. 2003.
http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf.

3. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher
reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. Nov 2004;19(11):1096-1103.

4. Marcus EN. The silent epidemic—the health effects of illiteracy. N Engl J Med. Jul 27 2006;355(4):339-341.
5. Moore JO, Boyer EW, Safren S, et al. Designing interventions to overcome poor numeracy and improve medication
adherence in chronic illness, including HIV/AIDS. J Med Toxicol. Jun 2011;7(2):133-138.

6. van Eijken M, Tsang S, Wensing M, de Smet PA, Grol RP. Interventions to improve medication compliance in older
patients living in the community: a systematic review of the literature. Drugs Aging. 2003;20(3):229-240.

7. Halkitis PN, Shrem MT, Zade DD, Wilton L. The physical, emotional and interpersonal impact of HAART: exploring the
realities of HIV seropositive individuals on combination therapy. J Health Psychol. May 2005;10(3):345-358.

8. Stirratt MJ, Remien RH, Smith A, et al. The role of HIV serostatus disclosure in antiretroviral medication adherence.
AIDS Behav. Sep 2006;10(5):483-493.

9. Carr RL, Gramling LF. Stigma: a health barrier for women with HIV/AIDS. J Assoc Nurses AIDS Care. Sep-Oct
2004;15(5):30-39.
10. Mugavero MJ, Lin HY, Allison JJ, et al. Racial disparities in HIV virologic failure: do missed visits matter? J Acquir
Immune Defic Syndr. Jan 1 2009;50(1):100-108.
11. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV
infection. Ann Intern Med. Jul 4 2000;133(1):21-30.
12. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral
suppression. Clin Infect Dis. Oct 1 2006;43(7):939-941.
13. Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B. Intermediate highly active antiretroviral
therapy adherence thresholds and empirical models for the development of drug resistance mutations. J Acquir Immune
Defic Syndr. Mar 1 2008;47(3):397-399.
14. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug
users: comparison of self-report and electronic monitoring. Clin Infect Dis. Oct 15 2001;33(8):1417-1423.
15. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy
adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. May
2006;10(3):227-245.

16. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence.
AIDS Behav. Jan 2008;12(1):86-94.
17. Bieszk N, Patel R, Heaberlin A, Wlasuk K, Zarowitz B. Detection of medication nonadherence through review of
pharmacy claims data. Am J Health Syst Pharm. Feb 15 2003;60(4):360-366.
18. Raboud J, Li M, Walmsley S, et al. Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav. Oct
2011;15(7):1397-1409.
19. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A
comprehensive review. J Clin Pharm Ther. Oct 2001;26(5):331-342.
20. Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9(7):51-54, 58.

21. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active
antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-5

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.